Associating SARS-CoV-2 Serological Assays with Protection: Where the Field Stands

Research output: Contribution to journalEditorial

3 Scopus citations
Original languageEnglish
Pages (from-to)707-709
Number of pages3
JournalClinical chemistry
Issue number5
StatePublished - Apr 29 2021


  • 55 serological assays have received EUA. Nonetheless
  • COVID-19
  • SARS-CoV-2
  • The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 was met with a rapid introduction of commercially available serological assays for SARS-CoV-2 antibody detection. Soon after being declared an emergency in the US
  • as laboratories gained access to this unprecedented number of assays
  • exceeding the number of assays available for any other infectious disease and most other laboratory analytes. As a result of this rapid expansion and at times dubious quality
  • hundreds of serological assays for SARS-CoV-2 were introduced
  • serology
  • the Food and Drug Administration (FDA) began reviewing and regulating all SARS-CoV-2 serological assays under emergency use authorization (EUA). To date
  • the utility of SARS-CoV-2 serological testing remained unclear

Cite this